PAREA reacts to the largest randomised, controlled, double blind psilocybin therapy study

PAREA was quoted in a POLITICO article describing the recent COMPASS clinical trial published in the New England Journal of Medicine. When asked to comment on the prevalence of adverse events in this clinical trial he responded:
”The presumed promise of psychedelic therapies could be a factor and unmet expectations could have fueled feelings of hopelessness and despair amongst non-responders to treatment.”